Anti-VEGF Treatment Strategies for Wet AMD (original) (raw)
Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology
Gary Brown
Ophthalmology, 2008
View PDFchevron_right
SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration
Stephan Winnik
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2017
View PDFchevron_right
Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration
Karen Wai
American Journal of Ophthalmic Clinical Trials, 2018
View PDFchevron_right
Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies
Stephenie Tiew
BMJ Open Ophthalmology, 2019
View PDFchevron_right
Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review
Meri Vukicevic
Psychology, health & medicine, 2015
View PDFchevron_right
Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration: phase 1 and phase 2 trials in treatment-naïve and anti-VEGF pretreated patients
yusuf ali
View PDFchevron_right
Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
Bora Eldem
BMC Ophthalmology, 2020
View PDFchevron_right
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
Paris Tranos
Drug Design, Development and Therapy, 2013
View PDFchevron_right
Combination Therapy for Neovascular Age-related Macular Degeneration Refractory to Anti-Vascular Endothelial Growth Factor Agents
James Folk
Ophthalmology, 2013
View PDFchevron_right
Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration
Letícia Barroso
Arquivos Brasileiros de Oftalmologia
View PDFchevron_right
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
Shaker Mousa
BioDrugs, 2010
View PDFchevron_right
Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
Georgios D Panos
Medical hypothesis, discovery and innovation in ophthalmology, 2015
View PDFchevron_right
Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
Yasuo Kurimoto
Clinical ophthalmology (Auckland, N.Z.), 2017
View PDFchevron_right
Treatment Paradigms in Neovascular AMD
rishi singh
Current Ophthalmology Reports, 2013
View PDFchevron_right
Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration
Ágnes Borbándy
BMC Ophthalmology
View PDFchevron_right
Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using “Treat and Extend” Regimen
Polona Mekjavic
Frontiers in Medicine, 2018
View PDFchevron_right
Defining response to anti-VEGF therapies in neovascular AMD
Sajjad Mahmood
Eye (London, England), 2015
View PDFchevron_right
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
Pearse A Keane
Journal of ophthalmology, 2012
View PDFchevron_right
When Should Anti-Vascular Endothelial Growth Factor Treatment Be Stopped in Age-Related Macular Degeneration?
Salomon Velasco Cohen
American Journal of Ophthalmology, 2010
View PDFchevron_right
Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review
Manas Biswal
International journal of ophthalmology, 2016
View PDFchevron_right
Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration
Joel Pearlman
Ophthalmology, 2017
View PDFchevron_right
Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration
José Tuñón
Survey of Ophthalmology, 2009
View PDFchevron_right
Characterisation of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents
Vuong pham nguyen
Ophthalmology, 2018
View PDFchevron_right
Synergies of VEGF Inhibition and Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
Robert Gurny
Investigative Opthalmology & Visual Science, 2007
View PDFchevron_right
Long-lasting effects of anti-VEGF/photodynamic combination therapy in the treatment of exudative age-related macular degeneration: a retrospective chart review
Kent Small
Clinical Ophthalmology, 2014
View PDFchevron_right
Vascular endothelial growth factor and its inhibitor in age-related macular degeneration
Herbert Pinedo
Taiwan Journal of Ophthalmology, 2013
View PDFchevron_right
Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration
Devinder Chauhan
American Journal of Ophthalmology, 2012
View PDFchevron_right
Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD
George Lambrou
Journal of ophthalmology, 2016
View PDFchevron_right
Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration
Thomas Ciulla
Ophthalmology, 2011
View PDFchevron_right
The effect of sample medication use on subsequent anti-VEGF agent selection for neovascular age-related macular degeneration
Karen Wai
2021
View PDFchevron_right
Anti-VEGF for the management of diabetic macular edema
Mauricio Maia, Emmerson Badaró
Journal of immunology research, 2014
View PDFchevron_right
Anti-vascular endothelial growth factor and macular atrophy: an unanswered question
Edward Wylegala
Annals of Eye Science, 2018
View PDFchevron_right
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Sobha Sivaprasad
British Journal of Ophthalmology, 2014
View PDFchevron_right
Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review
augustine pereira
Bmj Open, 2015
View PDFchevron_right
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD
Figen Batioğlu
BMC ophthalmology, 2015
View PDFchevron_right